Syndax Pharmaceuticals (SNDX) Stock Price, News & Analysis

Company Overview

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.

Key Stats

• Today's Range: $15.50 to $16.91
• 50-Day Range: $15.83 to $21.81
• 52-Week Range: $14.50 to $25.34
• Volume: 5.05 million shs
• Average Volume: 1.53 million shs
• Market Capitalization: $1.35 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $36.00
• Consensus Rating: Moderate Buy

Syndax Pharmaceuticals Stock Analysis - MarketRank™

Syndax Pharmaceuticals scored higher than 69% of companies evaluated by MarketBeat, and ranked 358th out of 970 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Syndax Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.91, and is based on 10 buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

Syndax Pharmaceuticals has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Syndax Pharmaceuticals are expected to decrease in the coming year, from ($3.61) to ($3.74) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Syndax Pharmaceuticals is -4.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Syndax Pharmaceuticals is -4.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Syndax Pharmaceuticals has a P/B Ratio of 3.69. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

12.49% of the outstanding shares of Syndax Pharmaceuticals have been sold short.

Short Interest Ratio / Days to Cover

Syndax Pharmaceuticals has a short interest ratio ("days to cover") of 11.2, which indicates bearish sentiment.

Change versus previous month

Short interest in Syndax Pharmaceuticals has recently increased by 1.43%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Syndax Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Syndax Pharmaceuticals does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.4 / 5
• Environmental Score: -1.12

Percentage of Shares Shorted

12.49% of the outstanding shares of Syndax Pharmaceuticals have been sold short.

Short Interest Ratio / Days to Cover

Syndax Pharmaceuticals has a short interest ratio ("days to cover") of 11.2, which indicates bearish sentiment.

Change versus previous month

Short interest in Syndax Pharmaceuticals has recently increased by 1.43%, indicating that investor sentiment is decreasing.

News and Social Media

• Score: 3.7 / 5
• News Sentiment: 0.66

News Sentiment

Syndax Pharmaceuticals has a news sentiment score of 0.66. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.56 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 15 news articles for Syndax Pharmaceuticals this week, compared to 5 articles on an average week.

Search Interest

3 people have searched for SNDX on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.

MarketBeat Follows

6 people have added Syndax Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Syndax Pharmaceuticals insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 4.10% of the stock of Syndax Pharmaceuticals is held by insiders.

SNDX Stock Analysis - Frequently Asked Questions

How have SNDX shares performed this year?

Syndax Pharmaceuticals' stock was trading at $21.61 at the beginning of 2024. Since then, SNDX stock has decreased by 26.7% and is now trading at $15.83.
View the best growth stocks for 2024 here.

How were Syndax Pharmaceuticals' earnings last quarter?

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) released its quarterly earnings data on Tuesday, November, 5th. The company reported ($0.98) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.13) by $0.15. The company had revenue of $12.50 million for the quarter, compared to analyst estimates of $9.16 million.

When did Syndax Pharmaceuticals IPO?

Syndax Pharmaceuticals (SNDX) raised $66 million in an initial public offering (IPO) on Thursday, March 3rd 2016. The company issued 4,400,000 shares at $14.00-$16.00 per share. Morgan Stanley and Citigroup acted as the underwriters for the IPO and JMP Securities and Oppenheimer & Co. were co-managers.

Who are Syndax Pharmaceuticals' major shareholders?

Top institutional shareholders of Syndax Pharmaceuticals include Wellington Management Group LLP (5.84%), State Street Corp (4.42%), Point72 Asset Management L.P. (3.25%) and Geode Capital Management LLC (2.32%). Insiders that own company stock include Dennis Podlesak, William Meury, Keith Katkin, Pierre Legault, Briggs Morrison, Michael A Metzger, Alexander Nolte, Peter Ordentlich and Fabrice Egros.
View institutional ownership trends.

How do I buy shares of Syndax Pharmaceuticals?

Shares of SNDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Syndax Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Syndax Pharmaceuticals investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Arista Networks (ANET), Adobe (ADBE), Novo Nordisk A/S (NVO) and ServiceNow (NOW).

Company Calendar

• Last Earnings: 11/05/2024
• Today: 11/17/2024
• Fiscal Year End: 12/31/2024
• Next Earnings (Estimated): 2/25/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:SNDX
• CUSIP: N/A
• CIK: 1395937
• Web: www.syndax.com
• Phone: (781) 419-1400
• Fax: 781-419-1420
• Employees: 110
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $36.00
• High Stock Price Target: $49.00
• Low Stock Price Target: $23.00
• Potential Upside/Downside: +127.4%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.91
• Research Coverage: 11 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($3.63)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-209,360,000.00
• Net Margins: N/A
• Pretax Margin: -1,856.64%
• Return on Equity: -64.34%
• Return on Assets: -57.72%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 6.99
• Quick Ratio: 6.99

Sales & Book Value

• Annual Sales: $139.71 million
• Price / Sales: 9.67
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $4.29 per share
• Price / Book: 3.69

Miscellaneous

• Outstanding Shares: 85,360,000
• Free Float: 81,858,000
• Market Cap: $1.35 billion
• Optionable: Optionable
• Beta: 0.92